the.andyman schreef op 24 september 2020 15:13:
[...]
Als je wil meespelen voor de jackpot bij de test ontwikkelaars is Novacyt met Primerdesign degene die je in je porto wil hebben.
ik copy-paste nog even het laatste Reuters bericht over ALNOV zoveel puntjes zoveel kansen
Sept 17 (Reuters) - Novacyt SA ALNOV.PA : * H1 OPERATING PROFIT 48.3 MILLION EUR VERSUS -700,000 EUR LOSS YEAR AGO * HALF YEAR PROFIT AFTER TAX 40.2 MILLION EUR VERSUS -1.2 MILLION EUR LOSS YEAR AGO
* H1 REVENUE 72.4 MILLION EUR VERSUS 7.2 MILLION EUR YEAR AGO * PERFORMANCE PROVIDES PERIOD END CASH OF EUR 19.7M, FOLLOWING REPAYMENT OF ALL DEBT AND SIGNIFICANT INVESTMENT IN INVENTORY *
VISIBILITY OF ORDERS FOR COMPANY'S COVID-19 PRODUCT PORTFOLIO SUGGESTS H2 2020 PERFORMANCE ON TRACK TO EXCEED THAT OF H1 2020
*DEVELOPING, TOGETHER WITH A PARTNER, A SEROLOGY (ANTIBODY) TEST TO DETECT PAST INFECTION OF COVID-19, WITH LAUNCH EXPECTED IN Q4 2020 *
NEAR-TERM FOCUS IS TO DELIVER STRONG ORGANIC REVENUE GROWTH IN CORE BUSINESS * CORE BUSINESS: DIRECTORS BELIEVE DEMAND FOR ITS PRODUCTS WILL CONTINUE TO GROW INTO AT LEAST H1 2021 AS COVID-19 TESTING CONTINUES *
MEDIUM-TERM: EXPECTS TO LEVERAGE REPUTATION, MARKET INTELLIGENCE, RELATIONSHIPS DEVELOPED DURING COVID-19 RESPONSE TO COMMERCIALISE NEW PRODUCTS * DIRECTORS EXPECT TO SUPPLEMENT PRODUCT PORTFOLIO AND EXPAND CORE CAPABILITIES THROUGH EXECUTING SELECTIVE AND ACCRETIVE M&A AT RIGHT TIME * DIRECTORS REITERATE GUIDANCE ANNOUNCED ON 13 JULY 2020 Source text